FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068543068> ?p ?o ?g. }

• W2068543068 endingPage "1006" @default.
• W2068543068 startingPage "1003" @default.
• W2068543068 abstract "A group of authors from the USA evaluated the efficacy and tolerability of tolterodine extended‐release on objective and subjective endpoints in men with an overactive bladder. They found that it significantly reduced incontinent episodes and improved patient perception of treatment benefit in men with an overactive bladder OBJECTIVE To evaluate the efficacy and tolerability of tolterodine extended‐release (ER) on objective and subjective endpoints in men with overactive bladder (OAB) and urgency urinary incontinence (UI). PATIENTS AND METHODS This was a post hoc analysis of data collected from men with OAB enrolled in a 12‐week, double‐blind, placebo‐controlled trial of tolterodine ER (4 mg once daily; tolterodine ER registration trial) and included men with urinary frequency (≥8 micturitions/24 h) and urgency UI (≥5 episodes/week). UI episodes were assessed using 7‐day bladder diaries. Patient perception of treatment benefit was evaluated after 12 weeks. Adverse events (AEs) were recorded throughout the study. RESULTS In all, 163 men with OAB (placebo, 86; tolterodine ER, 77; mean age 65 years) were evaluated. Baseline demographics and clinical characteristics were similar for the two treatment groups. Compared with placebo, tolterodine ER significantly reduced weekly UI episodes (median % change, −71% vs − 40%, P < 0.05; mean numeric change, − 11.9 vs −5.9, P = 0.02). Men receiving tolterodine ER had fewer micturitions/24 h, but this was not a significant difference from placebo (median % change, −12% vs − 4%, P = 0.22). Significantly more men treated with tolterodine‐ER (63%) than placebo‐treated men (46%) reported a benefit of treatment after 12 weeks ( P = 0.04). The most commonly reported AEs associated with tolterodine‐ER vs placebo were dry mouth (16% vs 7%), constipation (4% vs 9%), dyspepsia (4% vs 1%), dizziness (5% vs 1%), and somnolence (3% vs 1%). One of the men receiving tolterodine ER had symptoms suggestive of urinary retention that led to his withdrawal from the study. None of the men had acute urinary retention requiring catheterization. CONCLUSION In men with OAB and urgency UI, tolterodine ER was well tolerated and significantly reduced episodes of urgency UI, and improved patient perception of treatment benefit." @default.
• W2068543068 created "2016-06-24" @default.
• W2068543068 creator A5001479798 @default.
• W2068543068 creator A5049019006 @default.
• W2068543068 creator A5081214299 @default.
• W2068543068 creator A5085416965 @default.
• W2068543068 creator A5091477558 @default.
• W2068543068 creator A5091902641 @default.
• W2068543068 date "2006-04-06" @default.
• W2068543068 modified "2023-10-17" @default.
• W2068543068 title "Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence" @default.
• W2068543068 cites W1967031158 @default.
• W2068543068 cites W1968860914 @default.
• W2068543068 cites W1976319415 @default.
• W2068543068 cites W2005182544 @default.
• W2068543068 cites W2009593049 @default.
• W2068543068 cites W2026599479 @default.
• W2068543068 cites W2035001907 @default.
• W2068543068 cites W2035527398 @default.
• W2068543068 cites W2045828646 @default.
• W2068543068 cites W2065814656 @default.
• W2068543068 cites W2072658132 @default.
• W2068543068 cites W2092898101 @default.
• W2068543068 cites W2094970779 @default.
• W2068543068 cites W2123804835 @default.
• W2068543068 cites W2128613789 @default.
• W2068543068 cites W2134928141 @default.
• W2068543068 cites W4247900695 @default.
• W2068543068 cites W4294545090 @default.
• W2068543068 doi "https://doi.org/10.1111/j.1464-410x.2006.06068.x" @default.
• W2068543068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16643482" @default.
• W2068543068 hasPublicationYear "2006" @default.
• W2068543068 type Work @default.
• W2068543068 sameAs 2068543068 @default.
• W2068543068 citedByCount "78" @default.
• W2068543068 countsByYear W20685430682012 @default.
• W2068543068 countsByYear W20685430682013 @default.
• W2068543068 countsByYear W20685430682014 @default.
• W2068543068 countsByYear W20685430682015 @default.
• W2068543068 countsByYear W20685430682016 @default.
• W2068543068 countsByYear W20685430682017 @default.
• W2068543068 countsByYear W20685430682018 @default.
• W2068543068 countsByYear W20685430682019 @default.
• W2068543068 countsByYear W20685430682020 @default.
• W2068543068 countsByYear W20685430682021 @default.
• W2068543068 countsByYear W20685430682022 @default.
• W2068543068 countsByYear W20685430682023 @default.
• W2068543068 crossrefType "journal-article" @default.
• W2068543068 hasAuthorship W2068543068A5001479798 @default.
• W2068543068 hasAuthorship W2068543068A5049019006 @default.
• W2068543068 hasAuthorship W2068543068A5081214299 @default.
• W2068543068 hasAuthorship W2068543068A5085416965 @default.
• W2068543068 hasAuthorship W2068543068A5091477558 @default.
• W2068543068 hasAuthorship W2068543068A5091902641 @default.
• W2068543068 hasConcept C126322002 @default.
• W2068543068 hasConcept C126894567 @default.
• W2068543068 hasConcept C142724271 @default.
• W2068543068 hasConcept C197934379 @default.
• W2068543068 hasConcept C204787440 @default.
• W2068543068 hasConcept C27081682 @default.
• W2068543068 hasConcept C2778375690 @default.
• W2068543068 hasConcept C2778531004 @default.
• W2068543068 hasConcept C2778941218 @default.
• W2068543068 hasConcept C2781020410 @default.
• W2068543068 hasConcept C71924100 @default.
• W2068543068 hasConcept C77411442 @default.
• W2068543068 hasConceptScore W2068543068C126322002 @default.
• W2068543068 hasConceptScore W2068543068C126894567 @default.
• W2068543068 hasConceptScore W2068543068C142724271 @default.
• W2068543068 hasConceptScore W2068543068C197934379 @default.
• W2068543068 hasConceptScore W2068543068C204787440 @default.
• W2068543068 hasConceptScore W2068543068C27081682 @default.
• W2068543068 hasConceptScore W2068543068C2778375690 @default.
• W2068543068 hasConceptScore W2068543068C2778531004 @default.
• W2068543068 hasConceptScore W2068543068C2778941218 @default.
• W2068543068 hasConceptScore W2068543068C2781020410 @default.
• W2068543068 hasConceptScore W2068543068C71924100 @default.
• W2068543068 hasConceptScore W2068543068C77411442 @default.
• W2068543068 hasIssue "5" @default.
• W2068543068 hasLocation W20685430681 @default.
• W2068543068 hasLocation W20685430682 @default.
• W2068543068 hasOpenAccess W2068543068 @default.
• W2068543068 hasPrimaryLocation W20685430681 @default.
• W2068543068 hasRelatedWork W1983371621 @default.
• W2068543068 hasRelatedWork W1983573081 @default.
• W2068543068 hasRelatedWork W1996534025 @default.
• W2068543068 hasRelatedWork W2001645992 @default.
• W2068543068 hasRelatedWork W2019380449 @default.
• W2068543068 hasRelatedWork W2050061619 @default.
• W2068543068 hasRelatedWork W2065591897 @default.
• W2068543068 hasRelatedWork W2084288786 @default.
• W2068543068 hasRelatedWork W2089437227 @default.
• W2068543068 hasRelatedWork W2341135423 @default.
• W2068543068 hasVolume "97" @default.
• W2068543068 isParatext "false" @default.
• W2068543068 isRetracted "false" @default.
• W2068543068 magId "2068543068" @default.
• W2068543068 workType "article" @default.